SELLAS Life Sciences Group Inc buy Heureka
Start price
27.02.20
/
50%
€2.39
Target price
09.03.20
€3.00
Performance (%)
-23.10%
End price
09.03.20
€1.84
Summary
This prediction ended on 09.03.20 with a price of €1.84. The price of SELLAS Life Sciences Group Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -23.10%. Heureka has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 6.250% | 6.250% | 727.096% | 684.801% |
| iShares Core DAX® | 0.437% | 5.640% | 7.806% | 63.642% |
| iShares Nasdaq 100 | 1.057% | 0.282% | 27.239% | 88.123% |
| iShares Nikkei 225® | 1.769% | 0.406% | 49.266% | 83.527% |
| iShares S&P 500 | 0.368% | 1.920% | 22.336% | 68.755% |